1. Hexamethylene bisacetamide stimulates the expression of human immunodeficiency virus long terminal repeat sequences in rat and human fibroblasts.
- Author
-
Zoumpourlis V and Spandidos DA
- Subjects
- Acetamides toxicity, Animals, Antineoplastic Agents toxicity, Cell Division drug effects, Cell Line, Transformed, Chloramphenicol O-Acetyltransferase genetics, Chloramphenicol O-Acetyltransferase metabolism, Fibroblasts drug effects, Fibroblasts enzymology, HIV-1 drug effects, Humans, Rats, Repetitive Sequences, Nucleic Acid genetics, Stimulation, Chemical, Transcription, Genetic drug effects, Transfection, Acetamides pharmacology, Antineoplastic Agents pharmacology, Fibroblasts physiology, Gene Expression drug effects, HIV-1 genetics, Repetitive Sequences, Nucleic Acid drug effects
- Abstract
We have employed a recombinant plasmid, pBHIV1, carrying the long terminal repeat (LTR) sequence of the human immunodeficiency virus-1 (HIV-1) linked to the reporter chloramphenicol acetyl transferase (CAT) gene and to the aminoglycoside phosphotransferase (aph) gene as a selectable marker. We have introduced pBHIV1 in rat 208F and human MRCSV40TGR fibroblasts and obtained stable geneticin resistant RFBHIV1-1 and SVTGHIV1-1 cells, respectively. Both transfectant cells express CAT activity from the HIV LTR promoter. The response to anti-neoplastic drug hexamethylene bisacetamide (HMBA) was studied on the LTR regulated CAT activity in both cell lines. It was found that HMBA at 5mM concentration stimulates the expression of CAT from the HIV LTR in rat and human cells by 28- and 1.9-fold, respectively.
- Published
- 1992
- Full Text
- View/download PDF